GlassScriptPhysician profile
Emylee Morgan Brown
NPI 1619756210
$3,944.05
in general payments reported to CMS, 2019-2025
34 companies · $2,084 in 2025
The $2,084 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $194 · 2024: $1,666 · 2025: $2,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,944.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $508.50 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $378.82 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Biotech, INC. | $307.10 | 2024-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $285.45 | 2024-2025 | Tepezza, Repatha, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.08 | 2024-2025 | Xifaxan, Trulance |
| Ibsa Pharma INC. | $206.22 | 2023-2025 | Licart, Tirosint, Flector |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.79 | 2024-2025 | Jardiance, Synjardy |
| Amneal Pharmaceuticals LLC | $179.05 | 2024-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $168.46 | 2023-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $159.35 | 2024-2025 | |
| Beta Bionics, INC. | $132.66 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Takeda Pharmaceuticals U.S.A., INC. | $132.65 | 2024-2025 | Entyvio |
| Insulet Corporation | $131.57 | 2023-2025 | Omnipod |
| Cequr Corporation | $121.20 | 2024-2025 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $93.36 | 2025 | Yorvipath |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $84.28 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $72.60 | 2024-2025 | Zenpep |
| Amphastar Pharmaceuticals, INC. | $68.39 | 2024-2025 | |
| Abbvie INC. | $64.05 | 2024-2025 | |
| Ardelyx, INC. | $59.54 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $50.79 | 2024-2025 | Dupixent |
| Abbott Laboratories | $49.82 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $44.98 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $36.32 | 2024 | |
| Nevro Corp. | $27.61 | 2024 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $27.48 | 2025 | |
| Sequel Med Tech, LLC | $26.27 | 2025 | Twiist |
| Fresenius Kabi USA, LLC | $19.07 | 2024 | Idacio |
| Qol Medical, LLC | $17.97 | 2025 | Sucraid |
| Corcept Therapeutics | $16.59 | 2024 | Korlym |
| Phathom Pharmaceuticals, INC. | $15.99 | 2025 | Voquezna |
| Acella Pharmaceuticals, LLC | $15.30 | 2025 | NP Thyroid 60 |
| Tolmar, INC. | $15.15 | 2024 | |
| Echosens North America, INC. | $12.59 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emylee Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.